22102-68-7

Usage

Uses

Used in Organic Synthesis:
N-(Hexacosanoyloxy)succinimide is used as a reagent in organic synthesis for the preparation of various chemical compounds. Its unique structure allows it to participate in a range of reactions, such as esterification, amidation, and other condensation reactions, making it a versatile building block for the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-(Hexacosanoyloxy)succinimide is used as an intermediate in the synthesis of drug molecules. Its ability to form esters and amides with various functional groups makes it a valuable component in the development of new drugs and drug candidates.
Used in Chemical Research:
N-(Hexacosanoyloxy)succinimide is also used in chemical research as a model compound to study various reaction mechanisms and to develop new synthetic methodologies. Its unique reactivity and properties provide insights into the behavior of similar compounds and contribute to the advancement of organic chemistry.
Used in Material Science:
In the field of material science, N-(Hexacosanoyloxy)succinimide can be used as a precursor to develop new materials with specific properties. Its ability to form esters and amides can be exploited to create novel polymers, coatings, and other materials with tailored characteristics for various applications.

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 506-46-7 1-hexacosanoic acid 
• 1892-57-5 N-(3-dimethylaminopropyl)-N-ethylcarbodiimide 

Downstream Products

• 4201-58-5 (2S,3R,4E)-2-(hexadecanoylamido)-4-octadecene-1,3-diol 

Relevant academic research and scientific papers

Efficient Divergent Synthesis of New Immunostimulant 4″-Modified α-Galactosylceramide Analogues

A synthesis strategy for the swift generation of 4″-modified α-galactosylceramide (α-GalCer) analogues is described, establishing a chemical platform to comprehensively investigate the structure-activity relationships (SAR) of this understudied glycolipid

POLYSACCHARIDE ANTIGEN-GLYCOLIPID CONJUGATE VACCINES

The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.

Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3

The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.

PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3

The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.

CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES

The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.

Synthesis and biological activities of 5-thio-α-GALCERS

NKT cells, a unique subset of T cells that recognizes glycolipid antigens presented by CD1d molecules, are believed to produce key cytokines of both Th1 and Th2 T cells and are thus involved in the control of several types of immune response. As an active glycolipid antigen having α-galactosyl ceramide core structure, KRN7000 showed promising immunostimulation activity and was selected as an anticancer drug candidate for further clinical application. In this report, three new KRN7000 structural analogues were designed and synthesized, in which the ring oxygen of the galactopyranose residue is replaced by a sulfur atom along with the variation on the lipid chain. Their abilities for stimulating mouse NKT cells to produce IFN-γ and IL-4 were evaluated both in vivo and in vitro.

Syntheses and biological activities of KRN7000 analogues having aromatic residues in the acyl and backbone chains with varying stereochemistry

KRN7000 is an important ligand identified for CD1d protein of APC, and KRN7000/CD1d complex can stimulate NKT cells to release a broad range of bioactive cytokines. In an effort to understand the structure-activity relationships, we have carried out synth

Practical synthesis of KRN7000 from phytosphingosine

The efficient and practical synthesis of die biologically important a-galactosylceramides, KRN7000, from phytosphingosine has been achieved in six steps in high overall yield.